These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 11943104

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database.
    Zhao SZ, Reynolds MW, Lejkowith J, Whelton A, Arellano FM.
    Clin Ther; 2001 Sep; 23(9):1478-91. PubMed ID: 11589261
    [Abstract] [Full Text] [Related]

  • 3. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
    Senna G, Bilò MB, Antonicelli L, Schiappoli M, Crivellaro MA, Bonadonna P, Dama AR.
    Eur Ann Allergy Clin Immunol; 2004 Jun; 36(6):215-8. PubMed ID: 15329003
    [Abstract] [Full Text] [Related]

  • 4. Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin.
    Brinker A, Goldkind L, Bonnel R, Beitz J.
    Drugs Aging; 2004 Jun; 21(7):479-84. PubMed ID: 15132714
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A comparison of the renal and cardiovascular safety of celecoxib and rofecoxib.
    Schoors D.
    Clin Ther; 2002 Mar; 24(3):468-9; author reply 469-70. PubMed ID: 11952030
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs.
    Phelan KM, Mosholder AD, Lu S.
    J Clin Psychiatry; 2003 Nov; 64(11):1328-34. PubMed ID: 14658947
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cardiovascular events and COX-2 inhibitors.
    Fleming M.
    JAMA; 2001 Dec 12; 286(22):2808; author reply 2811-2. PubMed ID: 11735742
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Specific inhibitors of cyclooxygenase type 2] ].
    Tomasová-Studýnková J.
    Vnitr Lek; 2002 May 12; 48(5):403-8. PubMed ID: 12061207
    [Abstract] [Full Text] [Related]

  • 16. Interaction of rofecoxib and celecoxib with warfarin.
    Schaefer MG, Plowman BK, Morreale AP, Egan M.
    Am J Health Syst Pharm; 2003 Jul 01; 60(13):1319-23. PubMed ID: 12901032
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC.
    Clin Exp Rheumatol; 2001 Jul 01; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.